The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Immune-mediated inflammatory disease therapeutics: past, present and future
Open accessAbstract
Immune-mediated inflammatory diseases are common and clinically diverse. Although they are currently incurable, the therapeutic armamentarium for immune-mediated inflammatory diseases has been transformed in the past two decades. We have moved from the wide application of broad-spectrum immune modulators to the routine use of agents with exquisite specificity, arising from monoclonal and molecular biotechnology and more recently from highly targeted medicinal chemistry. Here we describe key advances and lessons that drove this remarkable progress and thereafter reflect on the next steps in this ongoing journey. In this Perspective, McInnes and Gravallese highlight the remarkable progress made over the past 20 years in treating immune-mediated inflammatory diseases. The available therapies have progressed from broad-spectrum immune modulators to highly targeted biological and small-molecule agents as our understanding of disease mechanisms has advanced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Treating rheumatoid arthritis to target: recommendations of an international task force
Smolen, J. S., Aletaha, D., Bijlsma, J. W. J., Breedveld, F. C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123919 · Cited by 2,100
Self-citationSecukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
Kalil, A. C., Patterson, T. F., Mehta, A. K., Tomashek, K. M., Wolfe, C. R., Ghazaryan, V., Marconi, V. C., Ruiz-Palacios, G. M., Hsieh, L., Kline, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2031994 · Cited by 1,835
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
O'Shea, J. J., Schwartz, D. M., Villarino, A. V., Gadina, M., McInnes, I. B., & Laurence, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-051113-024537 · Cited by 1,599
Self-citationHueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Grigor, C., Capell, H., Stirling, A., McMahon, A. D., Lock, P., Vallance, R., Porter, D., & Kincaid, W. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16676-2 · Cited by 1,435
Trial of tocilizumab in giant-cell arteritis
Stone, J. H., Tuckwell, K., Dimonaco, S., Klearman, M., Aringer, M., Blockmans, D., Brouwer, E., Cid, M. C., Dasgupta, B., Rech, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613849 · Cited by 1,386
Cited by
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Lee, A. R. Y. B., Wong, S. Y., Chai, L. Y. A., Lee, S. C., Lee, M. X., Muthiah, M. D., Tay, S. H., Teo, C. B., Tan, B. K. J., Chan, Y. H., et al. (2022) · BMJ · doi:10.1136/bmj-2021-068632 · Cited by 498
Antidepressant psychopharmacology: is inflammation a future target?
Benedetti, F., Zanardi, R., & Mazza, M. G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000403 · Cited by 45
Recent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases
Pham, A.-T., Ghilardi, A. F., & Sun, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1127722 · Cited by 40
Liu, X., Chen, Y.-W., Xu, X., Smith, D., & Fan, F. (2026) · Toxicological Sciences · doi:10.1093/toxsci/kfag021 · Cited by 1
Metadata
- Authors
- McInnes, I. B., & Gravallese, E. M.
- Venue
- Nature Reviews Immunology
- Published
- 2021-09-13
- Volume
- 21
- Issue
- 10
- Pages
- 680-686
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- OpenAlex
- W3198961522
- Cited by
- 337
- References
- 61
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immune-mediated inflammatory disease therapeutics: past, present and future. https://app.cochat.ai/papers/10.1038/s41577-021-00603-1
- The paper
- McInnes, I. B., & Gravallese, E. M. (2021). Immune-mediated inflammatory disease therapeutics: past, present and future. Nature Reviews Immunology. https://doi.org/10.1038/s41577-021-00603-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.